TWI690517B - 作爲二肽基肽酶１抑制劑之特定（２ｓ）-ｎ-［（１ｓ）-１-氰基-２-苯基乙基］-１,４-氧氮雜環庚烷-２-甲醯胺 - Google Patents
作爲二肽基肽酶１抑制劑之特定（２ｓ）-ｎ-［（１ｓ）-１-氰基-２-苯基乙基］-１,４-氧氮雜環庚烷-２-甲醯胺 Download PDFInfo
- Publication number
- TWI690517B TWI690517B TW104102345A TW104102345A TWI690517B TW I690517 B TWI690517 B TW I690517B TW 104102345 A TW104102345 A TW 104102345A TW 104102345 A TW104102345 A TW 104102345A TW I690517 B TWI690517 B TW I690517B
- Authority
- TW
- Taiwan
- Prior art keywords
- ethyl
- cyano
- carboxamide
- phenyl
- oxazepan
- Prior art date
Links
- 0 *[C@@](C=CC(N(*)*)=O)NC([C@]1OCCCNC1)=O Chemical compound *[C@@](C=CC(N(*)*)=O)NC([C@]1OCCCNC1)=O 0.000 description 16
- YYDNBUBMBZRNQQ-UHFFFAOYSA-N Cc(cc1)ccc1S(C)(=O)=O Chemical compound Cc(cc1)ccc1S(C)(=O)=O YYDNBUBMBZRNQQ-UHFFFAOYSA-N 0.000 description 2
- TZFWDZFKRBELIQ-UHFFFAOYSA-N O=C(Nc1c2)Oc1ccc2Cl Chemical compound O=C(Nc1c2)Oc1ccc2Cl TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 description 2
- JUHNDZDRBYPGTN-UHFFFAOYSA-N Bc(cc1)ccc1C#C Chemical compound Bc(cc1)ccc1C#C JUHNDZDRBYPGTN-UHFFFAOYSA-N 0.000 description 1
- KSCFGLQAPWYWLS-LURJTMIESA-N COC(CCO[C@@H](CN)C(OC)=O)=O Chemical compound COC(CCO[C@@H](CN)C(OC)=O)=O KSCFGLQAPWYWLS-LURJTMIESA-N 0.000 description 1
- CGNKVOUTLIKVLF-KRWDZBQOSA-N COC([C@H](CN(Cc1ccccc1)Cc1ccccc1)O)=O Chemical compound COC([C@H](CN(Cc1ccccc1)Cc1ccccc1)O)=O CGNKVOUTLIKVLF-KRWDZBQOSA-N 0.000 description 1
- SWQCPDIPYFBOKS-YFKPBYRVSA-N COC([C@H](CN1)OCCC1=O)=O Chemical compound COC([C@H](CN1)OCCC1=O)=O SWQCPDIPYFBOKS-YFKPBYRVSA-N 0.000 description 1
- YXPHWYUXONKHHS-UHFFFAOYSA-N C[I](C)c1ccc(C(N)=O)c(F)c1 Chemical compound C[I](C)c1ccc(C(N)=O)c(F)c1 YXPHWYUXONKHHS-UHFFFAOYSA-N 0.000 description 1
- WCWJGAFMGPMBQG-FPOVZHCZSA-N Cc(cc(cc1N2C)-c3ccc(C[C@@H](C#N)NC([C@H]4OCCCNC4)=O)cc3)c1OC2=O Chemical compound Cc(cc(cc1N2C)-c3ccc(C[C@@H](C#N)NC([C@H]4OCCCNC4)=O)cc3)c1OC2=O WCWJGAFMGPMBQG-FPOVZHCZSA-N 0.000 description 1
- DIGPPPDFNJERKC-UHFFFAOYSA-N Cc(cc1)cc(N2C)c1OCC2=O Chemical compound Cc(cc1)cc(N2C)c1OCC2=O DIGPPPDFNJERKC-UHFFFAOYSA-N 0.000 description 1
- NWAOJSPGUJUCDY-UHFFFAOYSA-N Cc(cc1)cc(N2CCOC)c1SC2=O Chemical compound Cc(cc1)cc(N2CCOC)c1SC2=O NWAOJSPGUJUCDY-UHFFFAOYSA-N 0.000 description 1
- PHKPGQBKGWGMRF-UHFFFAOYSA-N Cc(cc1F)cc(N2CC(F)F)c1OC2=O Chemical compound Cc(cc1F)cc(N2CC(F)F)c1OC2=O PHKPGQBKGWGMRF-UHFFFAOYSA-N 0.000 description 1
- VUBUFNCQOHLTKS-UHFFFAOYSA-N OCCCN(CC(COCc1ccccc1)O)Cc1ccccc1 Chemical compound OCCCN(CC(COCc1ccccc1)O)Cc1ccccc1 VUBUFNCQOHLTKS-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931090P | 2014-01-24 | 2014-01-24 | |
| US61/931,090 | 2014-01-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201612167A TW201612167A (en) | 2016-04-01 |
| TWI690517B true TWI690517B (zh) | 2020-04-11 |
Family
ID=52432834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104102345A TWI690517B (zh) | 2014-01-24 | 2015-01-23 | 作爲二肽基肽酶１抑制劑之特定（２ｓ）-ｎ-［（１ｓ）-１-氰基-２-苯基乙基］-１,４-氧氮雜環庚烷-２-甲醯胺 |
Country Status (38)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| EP3490566A4 (en) * | 2016-07-29 | 2020-03-11 | Insmed Incorporated | DETERMINED (2S) -N - [(1S)] - 1-CYANO-2-PHENYLETHYL-1,4-OXAZEPAN-2-CARBOXAMIDES FOR TREATING BRONCHIEKTASIS |
| KR20200118103A (ko) * | 2018-02-07 | 2020-10-14 | 인스메드 인코포레이티드 | Anca 관련 혈관염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| HRP20250115T1 (hr) | 2018-03-01 | 2025-05-23 | Astrazeneca Ab | Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid |
| CA3106269A1 (en) * | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| CA3106270A1 (en) * | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
| CN111689923B (zh) * | 2019-03-12 | 2022-11-08 | 中国科学院上海药物研究所 | 一个具有逆转肿瘤多药耐药活性的环脂肽化合物、其制备方法及用途 |
| EP4048280A4 (en) * | 2019-10-23 | 2023-11-15 | Chong Kun Dang Pharmaceutical Corp. | Compositions for preventing or treating chronic obstructive pulmonary diseases (copd) |
| EP4182700A4 (en) | 2020-07-20 | 2024-11-13 | Insmed Incorporated | METHODS FOR EXTRACTING NEUTROPHIL SERINE PROTEASES AND TREATMENT OF DIPETIDYL PEPTIDASE-1-MEDIATED DISEASES |
| KR20230084134A (ko) * | 2020-08-26 | 2023-06-12 | 하이스코 파마수티컬즈 피티이. 엘티디. | 디펩티딜 펩티다제 1의 저해제로서 작용하는 니트릴 유도체 및 이의 용도 |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN114159446A (zh) * | 2020-09-11 | 2022-03-11 | 中国科学院上海营养与健康研究所 | 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用 |
| CA3199568A1 (en) * | 2020-12-04 | 2022-06-09 | Reistone Biopharma Company Limited | Small molecule inhibitor of cathepsin c and medicinal use thereof |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| WO2022140516A1 (en) * | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
| US20240150335A1 (en) * | 2021-02-05 | 2024-05-09 | Medshine Discovery Inc. | Fused ring derivatives containing 1,4-oxazepane |
| WO2022232573A1 (en) * | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis |
| CA3236069A1 (en) * | 2021-10-29 | 2023-05-04 | Ariel Teper | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis |
| CN115925696A (zh) * | 2021-10-29 | 2023-04-07 | 瑞石生物医药有限公司 | 一种1-氰基-2-苯基乙基甲酰胺衍生物及其用途 |
| CN116332937A (zh) * | 2021-12-23 | 2023-06-27 | 杭州邦顺制药有限公司 | 二肽基肽酶ⅰ抑制剂及其用途 |
| WO2023134656A1 (zh) | 2022-01-11 | 2023-07-20 | 上海壹典医药科技开发有限公司 | 一种肽基腈类化合物及其应用 |
| WO2023159120A1 (en) * | 2022-02-16 | 2023-08-24 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa |
| WO2023160579A1 (zh) | 2022-02-22 | 2023-08-31 | 四川海思科制药有限公司 | 一种二肽基肽酶1抑制剂多晶型物及其制备方法和用途 |
| MX2024010176A (es) | 2022-02-22 | 2024-08-27 | Haisco Pharmaceuticals Pte Ltd | Metodo de preparacion de un compuesto heterociclico que contiene nitrogeno. |
| WO2023160542A1 (zh) | 2022-02-22 | 2023-08-31 | 四川海思科制药有限公司 | 二肽基肽酶抑制剂化合物的盐及晶型 |
| CN114644562B (zh) * | 2022-04-29 | 2023-08-22 | 常州大学 | 具有红移荧光发射的有机小分子荧光化合物、制备方法及应用 |
| CA3258114A1 (en) | 2022-06-07 | 2025-03-20 | Reistone Biopharma Company Ltd | BENZO[C]CHROMANE COMPOUND POLYMORPH, ITS PREPARATION PROCESS AND ITS USE |
| CN119156391A (zh) | 2022-06-07 | 2024-12-17 | 瑞石生物医药有限公司 | 苯并[c]色满化合物的可药用盐、其多晶型及用途 |
| WO2023243601A1 (ja) | 2022-06-13 | 2023-12-21 | モジュラス株式会社 | アザシクロアルキルカルボニル環状アミン化合物 |
| EP4551554A1 (en) | 2022-07-06 | 2025-05-14 | Chiesi Farmaceutici S.p.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
| WO2024081889A1 (en) | 2022-10-14 | 2024-04-18 | Genesis Therapeutics, Inc. | 4h-pyrido[1,2-a]pyrimidin-4-one derivatives for treating cancer |
| CN119948034A (zh) * | 2022-10-26 | 2025-05-06 | 上海壹迪生物技术有限公司 | 一种新型肽基腈类化合物及其应用 |
| CN115785083A (zh) * | 2022-12-27 | 2023-03-14 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂及其制备方法 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2024173556A2 (en) * | 2023-02-15 | 2024-08-22 | Insmed Incorporated | Uses of certain 1,4-oxazepane-2-carboxamides as dpp1 inhibitors |
| CN120957728A (zh) * | 2023-03-23 | 2025-11-14 | 海思科医药集团股份有限公司 | 一种二肽基肽酶小分子抑制剂的药物组合物 |
| WO2025059526A1 (en) * | 2023-09-15 | 2025-03-20 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
| USD1099133S1 (en) * | 2024-02-01 | 2025-10-21 | Apple Inc. | Display screen or portion thereof showing a graphical user interface |
| WO2025214073A1 (en) * | 2024-04-12 | 2025-10-16 | Insmed Incorporated | Dipeptidyl peptidase 1 inhibitors and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201041889A (en) * | 2009-05-07 | 2010-12-01 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2782151B2 (ja) | 1993-07-16 | 1998-07-30 | 博 吉田 | 衝撃吸収柵用の端ストッパ |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6462076B2 (en) | 2000-06-14 | 2002-10-08 | Hoffmann-La Roche Inc. | Beta-amino acid nitrile derivatives as cathepsin K inhibitors |
| WO2002020804A1 (en) | 2000-09-08 | 2002-03-14 | Prozymex A/S | Rat cathepsin, dipeptidyl peptidase i (dppi): crystal structure, inhibitors and its uses |
| NZ524974A (en) | 2000-10-06 | 2005-10-28 | Tanabe Seiyaku Co | Aliphatic nitrogen-containing 5-membered ring compound |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| KR20050044660A (ko) | 2001-12-04 | 2005-05-12 | 에프. 호프만-라 로슈 아게 | 치환된 2-아미노-사이클로알칸카복스아마이드 및 시스테인프로테아제 저해제로서의 이의 용도 |
| US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
| WO2004076434A1 (en) | 2003-02-28 | 2004-09-10 | Aic | Dipeptidyl peptidase inhibitors |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| WO2004106289A1 (en) | 2003-05-30 | 2004-12-09 | Prozymex A/S | Protease inhibitors |
| JP2006527704A (ja) * | 2003-06-18 | 2006-12-07 | プロザイメックス・アクティーゼルスカブ | プロテアーゼ阻害剤 |
| ES2665758T3 (es) | 2004-04-07 | 2018-04-27 | Rinat Neuroscience Corp. | Procedimientos de tratamiento del dolor de cáncer de hueso mediante administración de un anticuerpo antagonista del factor de crecimiento neuronal |
| WO2005106012A2 (en) | 2004-04-28 | 2005-11-10 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1) |
| US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
| SE0401657D0 (sv) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | Chemical compounds |
| US20070218128A1 (en) | 2004-06-29 | 2007-09-20 | Poul Bertelsen | Manufacturing of Quick Release Pharmaceutical Compositions of Water Insoluble Drugs and Pharmaceutical Compositions Obtained By the Process of the Invention |
| US20090054358A1 (en) | 2004-07-19 | 2009-02-26 | The John Hopkins University | Flt3 inhibitors for immune suppression |
| CN105288630A (zh) | 2005-02-18 | 2016-02-03 | 阿布拉科斯生物科学有限公司 | 治疗剂的组合和给予方式以及联合治疗 |
| EP1896461A2 (en) | 2005-06-30 | 2008-03-12 | Amgen Inc. | Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer |
| US20080221093A1 (en) | 2007-03-07 | 2008-09-11 | Christian Gege | Metalloprotease inhibitors containing a heterocyclic moiety |
| WO2009026701A1 (en) | 2007-08-29 | 2009-03-05 | Methylgene Inc. | Sirtuin inhibitors |
| JP2010540526A (ja) | 2007-09-25 | 2010-12-24 | ノバルティス アーゲー | エアロゾル化されたバンコマイシンのような薬剤での肺障害の処置 |
| WO2009074829A1 (en) * | 2007-12-12 | 2009-06-18 | Astrazeneca Ab | Peptidyl nitriles and use thereof as dipeptidyl peptidase i inhibitors |
| US9315449B2 (en) | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| UY31867A (es) | 2008-06-06 | 2010-01-29 | Boehringer Ingelheim Int | Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992 |
| EP2376495A4 (en) | 2008-12-08 | 2012-10-31 | Vm Pharma Llc | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS |
| US20100256194A1 (en) | 2009-04-01 | 2010-10-07 | Bial - Portela & Ca, S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
| WO2010142985A1 (en) * | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| LT3150198T (lt) | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
| WO2011154677A1 (en) * | 2010-06-09 | 2011-12-15 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760 |
| IT1404036B1 (it) | 2010-12-17 | 2013-11-08 | Oto Melara Spa | Veicolo armato con struttura migliorata. |
| US8841463B2 (en) | 2011-02-11 | 2014-09-23 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin C inhibitors |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| JP6479476B2 (ja) | 2012-02-21 | 2019-03-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類 |
| MX355055B (es) | 2012-04-17 | 2018-04-03 | Astellas Pharma Inc | Compuesto heterociclico aromatico biciclico nitrogenado. |
| WO2014091443A1 (en) | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| EP2775304A1 (en) | 2013-03-07 | 2014-09-10 | Universitätsspital Basel | Methods for detecting inflammatory disorder |
| JP6437929B2 (ja) | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| WO2014140075A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| WO2014140078A1 (en) | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c |
| EP2970252B1 (en) | 2013-03-14 | 2020-06-03 | Boehringer Ingelheim International GmbH | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
| WO2015027039A1 (en) | 2013-08-22 | 2015-02-26 | Emory University | Devices and methods related to airway inflammation |
| SG11201601150WA (en) | 2013-09-09 | 2016-03-30 | Prozymex As | Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors |
| WO2015032942A1 (en) | 2013-09-09 | 2015-03-12 | Prozymex A/S | N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors |
| GB201400034D0 (en) | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| TW201622721A (zh) | 2014-04-10 | 2016-07-01 | 諾華公司 | Ｓ１ｐ調節劑之立即釋放劑量療法 |
| KR102447412B1 (ko) | 2014-05-15 | 2022-09-23 | 인스메드 인코포레이티드 | 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법 |
| WO2015180687A1 (en) | 2014-05-30 | 2015-12-03 | The University Of Hong Kong | Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers |
| JP6529575B2 (ja) | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| CN108047240B (zh) | 2014-09-12 | 2020-08-04 | 勃林格殷格翰国际有限公司 | 组织蛋白酶c的螺环化合物抑制剂 |
| AU2015345070A1 (en) | 2014-11-14 | 2017-04-20 | Boehringer Ingelheim International Gmbh | Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists |
| US10479781B2 (en) | 2015-03-05 | 2019-11-19 | Neuprozyme Therapeutics ApS | Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors |
| EP3490566A4 (en) | 2016-07-29 | 2020-03-11 | Insmed Incorporated | DETERMINED (2S) -N - [(1S)] - 1-CYANO-2-PHENYLETHYL-1,4-OXAZEPAN-2-CARBOXAMIDES FOR TREATING BRONCHIEKTASIS |
| KR20200118103A (ko) * | 2018-02-07 | 2020-10-14 | 인스메드 인코포레이티드 | Anca 관련 혈관염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| HRP20250115T1 (hr) | 2018-03-01 | 2025-05-23 | Astrazeneca Ab | Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid |
| CA3106270A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
| CA3106269A1 (en) | 2018-07-17 | 2020-01-23 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis |
| EP3955889A1 (en) | 2019-04-17 | 2022-02-23 | Azora Therapeutics, Inc. | Topical compositions and methods for treating inflammatory skin diseases |
| KR20220026538A (ko) | 2019-06-05 | 2022-03-04 | 에모리 유니버시티 | 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체 |
| WO2022140516A1 (en) | 2020-12-22 | 2022-06-30 | Insmed Incorporated | Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease |
| CN112920124B (zh) | 2021-01-29 | 2024-03-01 | 安徽医科大学 | 一种嘧啶-2,4-二胺类化合物及其制备方法与应用 |
| WO2022232573A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis |
| WO2022232420A1 (en) | 2021-04-29 | 2022-11-03 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer |
| CA3236069A1 (en) | 2021-10-29 | 2023-05-04 | Ariel Teper | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis |
| WO2023159120A1 (en) | 2022-02-16 | 2023-08-24 | Insmed Incorporated | Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa |
-
2012
- 2012-04-15 NO NO12774761A patent/NO2699580T3/no unknown
-
2015
- 2015-01-21 US US14/601,371 patent/US9522894B2/en active Active
- 2015-01-23 RS RS20180069A patent/RS56919B1/sr unknown
- 2015-01-23 PT PT171956121T patent/PT3323814T/pt unknown
- 2015-01-23 LT LTEP20173862.2T patent/LT3744714T/lt unknown
- 2015-01-23 KR KR1020167022665A patent/KR102417684B1/ko active Active
- 2015-01-23 CN CN201910716882.4A patent/CN110483492B/zh active Active
- 2015-01-23 PE PE2016001236A patent/PE20161218A1/es unknown
- 2015-01-23 AR ARP150100202A patent/AR099177A1/es active IP Right Grant
- 2015-01-23 FI FIEP20173862.2T patent/FI3744714T3/fi active
- 2015-01-23 HR HRP20180116TT patent/HRP20180116T1/hr unknown
- 2015-01-23 EP EP25150988.1A patent/EP4548972A3/en active Pending
- 2015-01-23 DK DK17195612.1T patent/DK3323814T3/da active
- 2015-01-23 PL PL17195612T patent/PL3323814T3/pl unknown
- 2015-01-23 RS RS20250323A patent/RS66709B1/sr unknown
- 2015-01-23 JP JP2016548068A patent/JP6469711B2/ja active Active
- 2015-01-23 ES ES15701577.7T patent/ES2658516T3/es active Active
- 2015-01-23 CA CA2935625A patent/CA2935625C/en active Active
- 2015-01-23 WO PCT/GB2015/050155 patent/WO2015110826A1/en not_active Ceased
- 2015-01-23 SM SM20250137T patent/SMT202500137T1/it unknown
- 2015-01-23 DK DK15701577.7T patent/DK3097086T3/en active
- 2015-01-23 EA EA201691375A patent/EA032794B1/ru unknown
- 2015-01-23 DK DK20173862.2T patent/DK3744714T3/da active
- 2015-01-23 MY MYPI2016702657A patent/MY194850A/en unknown
- 2015-01-23 SM SM20180058T patent/SMT201800058T1/it unknown
- 2015-01-23 SI SI201532060T patent/SI3744714T1/sl unknown
- 2015-01-23 PL PL15701577T patent/PL3097086T3/pl unknown
- 2015-01-23 HU HUE15701577A patent/HUE038274T2/hu unknown
- 2015-01-23 AP AP2016009322A patent/AP2016009322A0/en unknown
- 2015-01-23 NZ NZ722063A patent/NZ722063A/en unknown
- 2015-01-23 LT LTEP15701577.7T patent/LT3097086T/lt unknown
- 2015-01-23 CR CR20160327A patent/CR20160327A/es unknown
- 2015-01-23 HU HUE17195612A patent/HUE052421T2/hu unknown
- 2015-01-23 PL PL20173862.2T patent/PL3744714T3/pl unknown
- 2015-01-23 SM SM20200433T patent/SMT202000433T1/it unknown
- 2015-01-23 EP EP15701577.7A patent/EP3097086B1/en active Active
- 2015-01-23 CN CN201580005484.1A patent/CN105980367B/zh active Active
- 2015-01-23 HU HUE20173862A patent/HUE070606T2/hu unknown
- 2015-01-23 SI SI201530170T patent/SI3097086T1/en unknown
- 2015-01-23 LT LTEP17195612.1T patent/LT3323814T/lt unknown
- 2015-01-23 HR HRP20250302TT patent/HRP20250302T1/hr unknown
- 2015-01-23 ES ES20173862T patent/ES3018635T3/es active Active
- 2015-01-23 PT PT201738622T patent/PT3744714T/pt unknown
- 2015-01-23 MX MX2016009349A patent/MX368840B/es active IP Right Grant
- 2015-01-23 TW TW104102345A patent/TWI690517B/zh active
- 2015-01-23 PT PT157015777T patent/PT3097086T/pt unknown
- 2015-01-23 RS RS20200858A patent/RS60639B1/sr unknown
- 2015-01-23 BR BR112016016224-2A patent/BR112016016224B1/pt active IP Right Grant
- 2015-01-23 SG SG11201606052TA patent/SG11201606052TA/en unknown
- 2015-01-23 ES ES17195612T patent/ES2808060T3/es active Active
- 2015-01-23 SG SG10201701056QA patent/SG10201701056QA/en unknown
- 2015-01-23 EP EP20173862.2A patent/EP3744714B1/en active Active
- 2015-01-23 UY UY0001035963A patent/UY35963A/es not_active Application Discontinuation
- 2015-01-23 SI SI201531287T patent/SI3323814T1/sl unknown
- 2015-01-23 AU AU2015208932A patent/AU2015208932C1/en active Active
- 2015-01-23 NZ NZ734768A patent/NZ734768A/en unknown
- 2015-01-23 EP EP17195612.1A patent/EP3323814B1/en active Active
-
2016
- 2016-07-05 IL IL246614A patent/IL246614B/en active IP Right Grant
- 2016-07-13 DO DO2016000175A patent/DOP2016000175A/es unknown
- 2016-07-20 PH PH12016501439A patent/PH12016501439A1/en unknown
- 2016-07-25 CL CL2016001889A patent/CL2016001889A1/es unknown
- 2016-08-23 ZA ZA2016/05856A patent/ZA201605856B/en unknown
- 2016-11-08 US US15/346,411 patent/US9815805B2/en active Active
-
2017
- 2017-01-18 AU AU2017200338A patent/AU2017200338B2/en active Active
- 2017-06-11 IL IL252836A patent/IL252836A0/en active IP Right Grant
- 2017-09-19 US US15/708,634 patent/US10287258B2/en active Active
-
2018
- 2018-01-22 ZA ZA2018/00431A patent/ZA201800431B/en unknown
- 2018-02-05 CY CY20181100132T patent/CY1120049T1/el unknown
- 2018-04-30 AU AU2018202956A patent/AU2018202956B2/en active Active
-
2019
- 2019-01-16 JP JP2019005300A patent/JP6804570B2/ja active Active
- 2019-03-19 US US16/358,091 patent/US10669245B2/en active Active
- 2019-03-25 IL IL265611A patent/IL265611A/en unknown
- 2019-04-17 AU AU2019202675A patent/AU2019202675B2/en active Active
-
2020
- 2020-04-22 US US16/855,522 patent/US11117874B2/en active Active
- 2020-07-23 CY CY20201100674T patent/CY1123391T1/el unknown
- 2020-07-23 HR HRP20201147TT patent/HRP20201147T1/hr unknown
- 2020-12-02 JP JP2020200413A patent/JP7157791B2/ja active Active
-
2021
- 2021-02-08 US US17/170,641 patent/US11667615B2/en active Active
-
2022
- 2022-04-04 JP JP2022062548A patent/JP7336563B2/ja active Active
- 2022-09-09 US US17/942,111 patent/US11773069B2/en active Active
- 2022-09-09 US US17/942,106 patent/US11655221B2/en active Active
- 2022-09-10 US US17/942,121 patent/US11655223B2/en active Active
- 2022-09-10 US US17/942,123 patent/US11814359B2/en active Active
- 2022-09-10 US US17/942,122 patent/US11655224B2/en active Active
- 2022-09-10 US US17/942,112 patent/US11673871B2/en active Active
- 2022-09-10 US US17/942,120 patent/US11655222B2/en active Active
- 2022-09-15 US US17/946,024 patent/US11680049B2/en active Active
- 2022-09-16 US US17/946,112 patent/US11673872B2/en active Active
-
2023
- 2023-04-13 US US18/300,350 patent/US20230250071A1/en not_active Abandoned
- 2023-08-21 JP JP2023133935A patent/JP7628587B2/ja active Active
- 2023-12-08 US US18/533,894 patent/US12054465B2/en active Active
-
2024
- 2024-06-17 US US18/745,710 patent/US20240336582A1/en not_active Abandoned
-
2025
- 2025-01-29 JP JP2025012602A patent/JP7714823B2/ja active Active
- 2025-07-16 JP JP2025119347A patent/JP2025157389A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201041889A (en) * | 2009-05-07 | 2010-12-01 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI690517B (zh) | 作爲二肽基肽酶１抑制劑之特定（２ｓ）-ｎ-［（１ｓ）-１-氰基-２-苯基乙基］-１,４-氧氮雜環庚烷-２-甲醯胺 |